New cases of vasculitis after alemtuzumab

Affiliations

¹ Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
² Department of Neurology, University of California-San Francisco, San Francisco, CA, USA.

Comment

Christina J Azevedo et al. Mult Scler. 2020 Oct.

. 2020 Oct;26(12):1606-1608.

doi: 10.1177/1352458520908040. Epub 2020 Feb 21.

¹ Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
² Department of Neurology, University of California-San Francisco, San Francisco, CA, USA.

No abstract available

Comment on

ANCA-associated life-threatening systemic vasculitis after alemtuzumab treatment for multiple sclerosis.
Horisberger A, Pantazou V, Cuendet G, Ribi C, Dunet V, Théaudin M. Horisberger A, et al. Mult Scler. 2020 Oct;26(12):1599-1602. doi: 10.1177/1352458519895449. Epub 2020 Feb 21. Mult Scler. 2020. PMID: 32081100
Alemtuzumab-related eosinophilic central nervous system vasculitis.
Leach OA, Hilton DA, Adams W, Love S, Straukiene A. Leach OA, et al. Mult Scler. 2020 Oct;26(12):1602-1606. doi: 10.1177/1352458519898113. Epub 2020 Feb 21. Mult Scler. 2020. PMID: 32081101